Immunoregulatory effects of sulforaphane in pancreatic cancer
Continuos exposure of pancreatic cancer cells to dietary bioactive agents does not induce drucg resistance unlike chemotherapy
Dexamethasone-induced microRNA regulation for pancreatic cancer progression
Targeting of pancreatic cancer stem-like cells by MSC-delivered oncolytic adenoviruses
Sulforaphane renders androgen-independent stem-like prostate cancer stem cells sensitive to TRAIL
Triptolide from TCM abolishes NF-KB-signaling, EMT and Stem-like Features in a Hypoxic Microenvironment of Pancreatic Cancer
Porcine mesenchymal stem cells from bone marrow for human liver regeneration
Sulforaphane enhances effects of Sorafenib, Quercetin and chemotherapy towards pancreatic cancer stem-like cells
Sulforaphane potentiates gemcitabine mediated cytotoxicity towards pancreatic cancer stem-like cells
Marine sponge Crambe crambe for efficient elimination of pancreatic cancer stem cells
Enhanced gene therapy with TRAIL by bispecific antibody immuno therapy in advanced prostate and pancreatic cancer
Bispecific EpCAMxCD3 antibody eradicates tumors in vivo and potently stimulates lymphocytes in 3D tumor reconstruct system in vitro
Sulphoraphane eradicates pancreatic cancer stem cells by NF -kappa B
Glucocorticoid-induced therapy resistance in solid tumors
Mesenchymal stem cells (MSCs) and TRAIL-induced apoptosis in pancreatic and prostate carcinomas
Mesenchymal stem cells (MSC) and angiogenesis in pancreatic and prostate cancer